CJC-1295 + Ipamorelin Dosage Guide: The GH Secretagogue Stack Protocol

CJC-1295 and Ipamorelin are both growth hormone secretagogues — compounds that stimulate the pituitary gland to produce and release growth hormone (GH). However, they do so through different mechanisms, which is why they are frequently studied together as a complementary stack.

CJC-1295 (with DAC): - A GHRH (growth hormone-releasing hormone) analogue — it mimics the natural GHRH signal that tells the pituitary to produce GH - The DAC (Drug Affinity Complex) modification extends its half-life significantly — from minutes (for native GHRH) to approximately 6–8 days - Provides sustained, elevated baseline GH stimulation rather than sharp pulses - CJC-1295 without DAC (also called Modified GRF 1-29): shorter half-life (~30 minutes), used for more pulsatile GH stimulation

Ipamorelin: - A GHRP (growth hormone-releasing peptide) and ghrelin mimetic — stimulates GH release via the ghrelin receptor pathway - Known for being highly GH-selective: it stimulates GH release with minimal effect on cortisol or prolactin (unlike earlier GHRPs such as GHRP-2 and GHRP-6) - Half-life approximately 2 hours, producing a discrete GH pulse when injected

Why combine them: CJC-1295 (DAC) elevates baseline GHRH signalling; Ipamorelin provides a targeted GH pulse at the time of injection. The combination is thought to produce a synergistic increase in GH and downstream IGF-1 that is greater than either peptide alone — a finding supported by preclinical data.

*This guide is for educational purposes only. CJC-1295 and Ipamorelin are research peptides and are not approved medications in the UK. All use outside of authorised research contexts carries risk.*

Research protocols for CJC-1295/Ipamorelin combination use vary, but a commonly cited reference range provides a useful starting point for understanding the dosing landscape.

Typical research dose (per injection): - CJC-1295 (with DAC): 100–200 mcg, once or twice weekly (reflecting its long half-life) - CJC-1295 without DAC (Modified GRF 1-29): 100 mcg, administered at the same time as Ipamorelin - Ipamorelin: 100–300 mcg per injection, most commonly 200 mcg, injected 1–3 times daily

Most commonly cited research combination protocol: - CJC-1295 without DAC (Mod GRF 1-29): 100 mcg + Ipamorelin 200 mcg — co-administered in the same syringe or sequentially, typically 1–3 times daily - CJC-1295 with DAC: 2mg once or twice weekly — in combination with Ipamorelin administered separately at higher frequency

Why the 100mcg/200mcg ratio: The approximate 1:2 ratio (GHRH analogue to GHRP) reflects the relative potency of the two peptide classes in co-stimulating GH release at the pituitary level. Some researchers use equal doses; the 1:2 ratio is simply the most frequently documented in research community protocols.

Number of injections per day: - Most research protocols administer 1–3 times daily, with the pre-sleep injection typically considered most important for synchronising with the natural overnight GH pulse - Some protocols use 2x/day (morning and before bed) as a practical middle ground

*All dose information is based on published research literature and is provided for educational purposes only.*

Reconstituting CJC-1295 and Ipamorelin accurately is essential for research precision. The following covers standard reconstitution for typical commercial vial sizes.

Common vial sizes: - CJC-1295 (with DAC): typically 2mg vials - CJC-1295 without DAC (Mod GRF 1-29): typically 2mg vials - Ipamorelin: typically 2mg or 5mg vials

Reconstitution protocol:

1. Clean vial tops with an alcohol swab and allow to dry 2. Draw bacteriostatic water (BAC water) into a sterile syringe — do not use plain water (insufficient shelf life) 3. Slowly inject the BAC water against the side of the vial — do not spray directly onto the lyophilised powder 4. Gently swirl until fully dissolved — do not shake vigorously 5. Solution should be clear and colourless

Resulting concentrations (example):

| Vial | BAC Water Added | Concentration | |---|---|---| | CJC-1295 2mg | 2mL | 1,000 mcg/mL | | Ipamorelin 2mg | 2mL | 1,000 mcg/mL | | Ipamorelin 5mg | 2mL | 2,500 mcg/mL |

Syringe units (U-100 insulin syringe) at 1,000 mcg/mL: - CJC-1295 100 mcg = 10 units - Ipamorelin 200 mcg = 20 units - Total combined volume = 0.3 mL = 30 units

Can they be combined in one syringe? Many research protocols draw both peptides into the same syringe and inject once — this is a common practice. Stability data for mixed solutions is limited; most research community protocols suggest injecting within 30 minutes of mixing.

Storage: Store reconstituted peptides at 2–8°C. Typically stable for 4–6 weeks when stored correctly in BAC water.

The timing of CJC-1295/Ipamorelin administration is considered one of the most important variables in maximising research outcomes, because it directly interacts with the body's natural GH secretion patterns.

The natural GH pulse cycle: Growth hormone is not secreted continuously — it is released in discrete pulses, with the largest pulse occurring during deep sleep (slow-wave sleep), typically 60–90 minutes after falling asleep. This overnight pulse accounts for a significant proportion of daily GH secretion.

Why pre-sleep timing is preferred: - Administering GH secretagogues before bed allows them to amplify the natural nocturnal GH pulse rather than compete with or displace it - This is thought to more closely mimic the body's own GH rhythms compared to daytime dosing

Empty stomach requirement: - Glucose and insulin suppress GH secretion. Elevated insulin levels (from a recent meal) significantly blunt the GH response to secretagogues - Research protocols typically specify administration at least 2 hours post-meal, with the pre-sleep injection taken after the body has had time to return to a fasted metabolic state - Avoid carbohydrate-rich foods in the 2 hours before the pre-sleep injection

Multi-dose protocols (timing structure): - Once daily: Before bed (most common single-dose approach) - Twice daily: Morning (fasted) + before bed - Three times daily: Morning (fasted) + post-workout (fasted or with protein only) + before bed

Post-workout timing note: For research protocols examining recovery and body composition, a post-workout injection (when growth hormone levels are already elevated by exercise) is sometimes used as a second or third administration window.

Cycling protocols help research teams structure administration periods and rest periods. The most commonly cited cycle structure for CJC-1295/Ipamorelin research is the 5-on/2-off protocol.

5-on/2-off protocol: - Administer for 5 consecutive days, then take 2 days off (typically at the weekend) - Repeat continuously throughout the research period - The rationale: mirrors a natural working week pattern and provides regular rest intervals - Some researchers use continuous daily dosing (7 days/week) throughout a defined cycle period; others prefer the 5/2 approach to reduce potential pituitary downregulation

Typical research cycle length: - 8–12 weeks is the most commonly used duration for a defined research cycle - Some longer-term research protocols extend to 16–20 weeks with appropriate monitoring - Standard convention: off-cycle period roughly equal to on-cycle duration before repeating

Expected IGF-1 response: IGF-1 (insulin-like growth factor 1) is primarily produced in the liver in response to GH stimulation and serves as the most practical biomarker for GH axis activation.

• •Onset of IGF-1 elevation: Research data suggests IGF-1 levels begin to rise within 2–4 weeks of consistent CJC-1295/Ipamorelin administration
• •Peak IGF-1 levels: Typically observed at 4–8 weeks of sustained administration
• •Magnitude: Variable; research subjects with lower baseline IGF-1 typically show proportionally greater increases
• •Return to baseline: IGF-1 levels return to pre-administration levels within 4–8 weeks of cessation

Monitoring in research contexts: Blood IGF-1 measurement provides objective data on GH axis response. Fasting glucose monitoring is also recommended given GH's effects on insulin sensitivity.

*All information is for educational and research information purposes only. These compounds are not approved medications in the UK.*